Summary
Thirty-eight patients with adult acute lymphoblastic leukemia (ALL) or non-Hodgkin's lymphoma (NHL) were treated intravenously with (2″-R)-4′-o-Tetrahydropyranyladriamycin (THP) at a dose of 10 mg/m2 for 5 consecutive days. Seven complete and 15 partial responses were observed in 35 evaluable patients (overall response rate, 62.8%). Both antitumor activity and antitumor spectrum were similar to those for doxorubicin. Since the patients who had had chemotherapy previously, including other kinds of anthracycline, responded rather poorly to THP, cross-resistance between THP and other anthracyclines may be present. Leukopenia and thrombocytopenia were dose-limiting factors. Nausea and vomiting episodes were mild, and epilation was also minimal. Although the observation period was short and a cumulative dose was not large enough to evaluate cardiotoxicity, there were no abnormal EKG changes or clinical signs of cardiotoxicity in this study. THP is a potent antitumor agent in the treatment of lymphoid malignancies.
This is a preview of subscription content, log in via an institution to check access.
Similar content being viewed by others
References
Blum RH, Carter SK (1974) Adriamycin. A new anticancer drug with significant clinical activity. Ann Int Med 80: 249
Danchev D, Paintland M, Hayat M, Bourut C, Mathé G (1979) Low heart and skin toxicity of a tetrahydropyranyl derivative of adriamycin (THP-ADM) as observed by electron and light microscope. J Antibiot (Tokyo) 32: 1085
FAB Cooperative Group (1981) Themorphological classification of acute lymphoblastic leukemia: concordance among observers and clinical correlations. Br J Hematol 47: 553
Kimura K, THP study group (1986) A phase II study of (2″ R)-4′-o-Tetrahydropyreanyladriamycin (THP) in patients with hematological malignancies. Jpn J Cancer Chemother 13: 368
Kunimoto S, Miura K, Takahashi Y, Takeuchi T, Umezawa H (1983) Rapid uptake by cultured tumor cells and intracellular behavior of 4′-o-Tetrahydropyranyladriamycin. J Antibiot 36:312
Majima H (1983) Exploratory clinical study of 4′-o-Tetrahydropyranyl doxorubicin (THP-ADM) Phase I. Jpn J Cancer Chemother 10: 134
Nanba K, Sasaki N (1981) Histopathological classification of non-Hodgkin's lymphoma: comparison between the new Working Formulation and Japanese LSG classification. Naika 48: 14
O'Bryan RM, Luce LK, Talley RW, Gottlieb JA, Baker LH, Bonadonna G (1973) Phase II evaluation of adriamycin in human neoplasia. Cancer 32: 1
Ogawa M, Miyamoto H, Inagaki J, Horikoshi N, Ezaki K, Inoue K, Ikeda K, Usui N, Nakada H (1983) Phase I clinical trial of a new anthracycline, 4′ o-Tetrahydropyranyladriamycin. Jpn J Cancer Chemother 10: 129
Saito T, THP study group (1986) Phase II study of (2″ R)-4′-o-Tetrahydropyranyladriamycin (THP) in patients with solid tumor. Jpn J Cancer Chemother 13: 1060
Takagi T, Oguro M, Iwabuchi K (1984) Effects of single administration of tetrahydropyranyladriamycin (THP) in lymphoid malignancies. Jpn J Cancer Chemother 11: 1450
The non-Hodgkin's lymphoma pathologic classification project (1982) National Cancer Institute sponsored study of classification of non-Hodgkin's lymphomas. Cancer 49: 2112
Tsuruo T, Iida H, Tsukagoshi S, Sakurai Y (1981) 4′-o-Tetrahydropyranyladriamycin as a potential new antitumor agent. Cancer Res 42: 1462
Umezawa H, Takahashi Y, Kinoshita M, Naganawa H, Masuda T, Ishizuka M, Takastu K, Takeuchi T (1979) Tetrahydropyranyl derivatives of daunomycin and adriamycin. J Antibiot (Tokyo) 32: 1082
WHO (1979) WHO handbook for reporting results of cancer treatment. WHO, Geneva
Author information
Authors and Affiliations
Rights and permissions
About this article
Cite this article
Takagi, T., Oguro, M. (2″-R)-4′-o-Tetrahydropyranyladriamycin, a new anthracycline derivative; its effectiveness in lymphoid malignancies. Cancer Chemother. Pharmacol. 20, 151–154 (1987). https://doi.org/10.1007/BF00253970
Received:
Accepted:
Issue Date:
DOI: https://doi.org/10.1007/BF00253970